Am J Prev Med by Ekwueme, Donatus U. et al.
Treatment Costs of Breast Cancer Among Younger Women Aged 
19–44 Years Enrolled in Medicaid
Donatus U. Ekwueme, PhD, MS1, Benjamin T. Allaire, MS2, Gery P. Guy Jr., PhD, MPH1, 
Sarah Arnold, BA2, and Justin G. Trogdon, PhD3
1Division of Cancer Prevention and Control, CDC, Atlanta, Georgia
2RTI International, Research Triangle Park, North Carolina
3Department of Health Policy and Management, University of North Carolina at Chapel Hill, 
Chapel Hill, North Carolina
Abstract
Introduction—A few studies have examined the costs of breast cancer treatment in a Medicaid 
population at the state level. However, no study has estimated medical costs for breast cancer 
treatment at the national level for women aged 19–44 years enrolled in Medicaid.
Methods—A sample of 5,542 younger women aged 19–44 years enrolled in fee-for-service 
Medicaid with diagnosis codes for breast cancer in 2007 were compared with 4.3 million women 
aged 19–44 years enrolled in fee-for-service Medicaid without breast cancer. Nonlinear regression 
methods estimated prevalent treatment costs for younger women with breast cancer compared with 
those without breast cancer. Individual medical costs were estimated by race/ethnicity and by type 
of services. Analyses were conducted in 2013 and all medical treatment costs were adjusted to 
2012 U.S. dollars.
Results—The estimated monthly direct medical costs for breast cancer treatment among younger 
women enrolled in Medicaid was $5,711 (95% CI=$5,039, $6,383) per woman. The estimated 
monthly cost for outpatient services was $4,058 (95% CI=$3,575, $4,541), for inpatient services 
was $1,003 (95% CI=$708, $1,298), and for prescription drugs was $539 (95% CI=$431, $647). 
By race/ethnicity, non-Hispanic white women had the highest monthly total medical costs, 
followed by Hispanic women and non-Hispanic women of other race.
Conclusions—Cost estimates demonstrate the substantial medical costs associated with breast 
cancer treatment for younger Medicaid beneficiaries. As the Medicaid program continues to 
evolve, the treatment cost estimates could serve as important inputs in decision making regarding 
planning for treatment of invasive breast cancer in this population.
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Introduction
Breast cancer is the most common malignant tumor among U.S. women, accounting for 
about 30% of incident cancers.1 It is one of the most costly medical conditions to treat.2 
Women aged 18–44 years account for 11% of new cases.3 These women tend to experience 
more-aggressive types of breast cancer, requiring intensive and expensive treatment with 
lower survival rates compared with older women.4,5 The health and economic outcomes may 
be worse among younger women with lower SES, such as those enrolled in Medicaid. This 
may be due in part to Medicaid beneficiaries being more likely to present with advanced-
stage cancers than patients with private insurance.4,6–10
Access to breast cancer treatment is crucial for long-term survival. However, treatment costs 
can impose substantial financial burden, particularly for younger women and those of lower 
SES.11–15 Further, access to treatment and financial burden issues may be a greater 
challenge for Medicaid patients.13–15 For instance, in one colon cancer study, the authors 
found that 21% of Medicaid patients reported denial of treatment by healthcare providers.13
Few studies have examined breast cancer treatment costs in a Medicaid population.9,13,14,16 
These studies have been conducted in select states or small geographically defined settings, 
which may not generalize to other states, given the large variation in state Medicaid 
programs.9,13,14,16–18 No study has estimated costs for breast cancer treatment in a 
nationally representative Medicaid population for younger women. The purpose of this study 
is to present national-level prevalence cost estimates, representing monthly treatment costs 
on breast cancer for women aged 19–44 years enrolled in Medicaid in 2007. Further, this 
study reports total monthly individual medical costs by race/ethnicity, stratified into four 
mutually exclusive categories: non-Hispanic white (NHW), non-Hispanic black (NHB), non-
Hispanic other (NHO), and Hispanic, and by type of service (TOS, i.e., outpatient, inpatient, 
and prescription drugs).
Methods
Data and Study Population
The current study used Medicaid Analytic eXtract (MAX) claims and enrollment data in 
2007,19 which was the most recent year data were available at the start of this study. MAX 
data are maintained by the Centers for Medicare and Medicaid Services and contain data 
from all 50 states and the District of Columbia.19 The study sample included women aged 
19–44 years enrolled in fee-for-service Medicaid, which includes those in primary care case 
management and whose only managed care coverage was for dental. The study excluded 
populations with other insurance groups, such as dual Medicare–Medicaid enrollees and 
enrollees in capitated managed care plans, because their complete service use may not be 
reported in the database.20 In the Medicaid program, beneficiaries are not required to have a 
full year of enrollment, therefore, some are enrolled for relatively short periods of time 
during a calendar year.21
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Payments by Service Type
Because much of the MAX population was enrolled in Medicaid for less than a full calendar 
year, total Medicaid payments and payments by service types were analyzed by month to 
accurately reflect the healthcare needs of each individual. Three separate TOSs—inpatient, 
outpatient, and prescription drugs—were calculated using Centers for Medicare and 
Medicaid Services– generated TOS codes. Because the MAX data set did not provide 
predefined TOS payment, payments were derived from the MAX file types. The outpatient 
Medicaid files include services provided by physicians, other practitioners, outpatient 
hospitals, clinics, and nurse practitioners. The inpatient file contains complete stay records 
for enrollees who used inpatient services, including diagnoses, procedures, discharge status, 
length of stay, and payment amount. Prescription drug files in Medicaid include payments 
for drugs as well as durable medical equipment. Analysis of point of service was restricted 
to fee-for-service beneficiaries only. All medical treatment costs were adjusted to 2012 U.S. 
dollars using the Personal Health Care Expenditure Price Index.22
Breast Cancer Identification
Three ICD-9-CM diagnosis codes were used to classify beneficiaries with breast cancer: a 
malignant neoplasm of the female breast (174), carcinoma in situ of breast (233.0), or a 
history of malignant breast neoplasms (V10.3).23 Beneficiaries with any inpatient or long-
term care claims with any of these ICD-9-CM codes were identified as breast cancer 
patients. To exclude breast cancer screenings or other tests to rule out breast cancer, 
beneficiaries were also identified as having breast cancer if there were at least two outpatient 
claims with these ICD-9-CM codes on different days. Female enrollees aged 19–44 years 
not identified as having breast cancer were used as the comparison population in the study.
Matching Procedure
Propensity score was used to match younger women with breast cancer from the database to 
younger women without breast cancer. The propensity score estimates the probability of 
being in the breast cancer group based on patient characteristics using predicted probabilities 
via a probit regression. The predicted values from the probit regression summarize multiple 
patient characteristics into a single propensity score, with similar scores indicating overlap 
in patient characteristics.24 The probit model included the proportion of the year enrolled in 
Medicaid, age, race/ethnicity, state, a Charlson Comorbidity Index (CCI) exclusive of 
cancer, an indicator for cancer diagnosis, and 12 comorbid conditions. Nearest neighbor 
matching was used to pair a breast cancer patient with a non–breast cancer comparison 
woman. Because covariate balance may not hold for subsets of the matched sample, the 
authors rematched using nearest neighbor matching for each of the race/ethnicity subgroups.
25
Demographic variables in the MAX data included proportion of the year enrolled in 
Medicaid, age, race/ethnicity, state of residence, and Medicaid plan type. The proportion of 
the year enrolled was calculated as the number of months enrolled divided by 12. The age 
variable was coded into 5-year age categories: 19–23, 24–28, 29–33, 34–38, and 39–44 
years. The race/ethnicity variable was stratified into four mutually exclusive categories: 
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NHW, NHB, NHO, and Hispanic. State identifiers were included in matching to adjust for 
state-level effects, relating to the differences in state Medicaid benefits.
The CCI excluded diagnosis codes for cancers: any malignancy, leukemia and lymphoma, 
and metastatic solid tumors.26 To adjust for cancers not included in the CCI, two samples 
were matched on a single cancer variable, which included ovarian, colorectal, lung, cervical, 
skin, and leukemia and lymphoma. Because the CCI includes comorbidities that are most 
relevant to an older population, 12 conditions with prevalence of at least 0.5% (e.g., 
pregnancy, injuries, and hypertension) were included as covariates in the multivariable 
regression models.
Statistical Analysis
Data on medical costs are usually skewed and using linear regressions may produce biased 
estimates.27 In this study, a fraction of the study sample had zero medical costs (8%) and 
some have extremely high medical costs. For instance, 0.85% of beneficiaries have treatment 
costs more than ten times the sample mean. To reduce the influence of extreme cases and 
potential bias in the estimates, the authors followed the procedures in Manning and 
Mullahy27 and Buntin and Zaslavsky28 and performed the Modified Park Test. The two-part 
generalized linear model with a gamma distribution and a log link was used.27,28 The first 
part of the two-part model was a logistic regression to predict the probability of any medical 
expenditure. The second part was a generalized linear model comprised of individuals with 
positive medical expenditures. The Modified Park Test was performed after running the 
regressions. The results indicated that the gamma family of distributions was the best fit in 
most cases (and second best in all others). Therefore, a gamma family distribution was used 
for all specifications for consistency and the log link passed all specification tests.
Costs attributable to breast cancer were calculated by comparing predicted costs for younger 
women with breast cancer to predicted costs for those without breast cancer, while holding 
all other variables constant at mean values. The delta method was used to compute SEs for 
the estimates. All analyses were conducted in 2013 in Stata, version 13.1.
Results
The sample included 5,542 women aged 19–44 years who were Medicaid enrollees with 
breast cancer and > 4.3 million Medicaid enrollees without breast cancer. Table 1 presents 
summary statistics for the breast cancer, comparison, and matched comparison samples. The 
breast cancer group was older than the comparison sample; almost 64% of the breast cancer 
sample was aged 39–44 years, compared with 13% of the comparison sample. The breast 
cancer group also had a slightly higher proportion of Hispanic women. For the breast cancer 
sample, the unadjusted differences in the total monthly medical costs were four times higher 
than the comparison group ($3,492 vs $850, p < 0.01).
Data presented in Table 1 indicate that the matching procedure was successful; all covariates 
were balanced at the 95% level. State indicators (results available upon request) also 
balanced at the 95% level. Even after matching, the differences in medical expenditures 
between the breast cancer and matched comparison samples were large ($3,492 vs $1,184; p 
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< 0.01). The results of matching for subsamples by race/ethnicity are presented in Appendix 
Tables 1–4 (available online).
Figure 1 presents the estimated monthly attributable breast cancer medical costs by point of 
service and race/ethnicity. The estimated total monthly medical cost was $5,838 (95% 
CI=4,894, $6,782) for NHWs, $5,487 (95% CI=$3,741, $7,233) for Hispanics, and $4,912 
(95% CI=$3,406, $6,418) for NHBs. In general, the estimated total monthly treatment costs 
by race/ethnicity were statistically significant at p < 0.01. By point of service, the estimated 
medical costs for outpatient services for NHOs was $4,274 (95% CI=$2,315, $6,233), which 
was significantly higher than NHWs ($4,265, 95% CI=$3,540, $4,990). For inpatient 
services, Hispanics had the highest estimated monthly medical cost ($1,036, 95% CI=$420, 
$1,652), followed by NHWs ($900, 95% CI=$475, $1,325). For prescription drug costs, 
NHWs had highest estimated medical cost of $695 (95% CI=$514, $876) and NHOs had 
significantly lowest cost of $352 (95% CI=$136, $568).
Estimates for the two-part regression models by point of service are presented in Table 2. 
The total monthly medical cost attributable to breast cancer was estimated to be $5,711 
(95% CI=$5,039, $6,383). The estimated cost for each point of service was $4,058 (95% 
CI=$3,575, $4,541) for outpatient, $1,003 (95% CI=$708, $1,298) for inpatient, and $539 
(95% CI=$431, $647) for prescription drug costs. These estimated monthly medical costs 
were significant at p < 0.01.
Discussion
This study provides national prevalence estimates of monthly medical costs for breast cancer 
treatment among women aged 19–44 years enrolled in Medicaid. The estimated monthly 
direct medical costs ranged from $5,039 to $6,383 per woman. By point of service, the 
estimates ranged from $3,575 to $4,541 for outpatient services, $708 to $1,298 for inpatient 
services, and $430 to $647 for prescription drug costs. NHW women had the highest 
monthly total medical costs, whereas NHO women had the lowest. The cost estimates 
reported in this study demonstrate the substantial medical costs associated with breast cancer 
treatment among younger Medicaid beneficiaries. These findings under-score the fact that 
Medicaid beneficiaries have a higher probability of being diagnosed with advanced-stage 
cancers, including breast cancer, than privately insured women.7,29,30
Patterns of monthly medical costs by point of service differed by race/ethnicity. NHO and 
NHW women had significantly higher medical costs for outpatient services than monthly 
costs of treating other racial/ethnic groups. For inpatient service, Hispanic and NHW women 
had significantly higher medical costs than costs of treating other racial/ethnic groups. On 
the other hand, the monthly medical costs of prescription drugs were significantly higher for 
NHW and Hispanic women than that of other racial/ethnic groups. Therefore, interpreting 
the variability in monthly treatment costs as disparities may not be straightforward. This is 
because breast cancer treatment costs vary by stage of diagnosis and subsequent prognosis, 
types of chemotherapeutic choices recommended to the patient and associated costs, and 
other anticancer treatment that the patient may undertake on a month-to-month basis. 
Further, the study data lack clinical information to ascertain the severity of breast cancer in 
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the study population. Therefore, the authors are faced with the same difficulties that previous 
studies have encountered: the inability to identify whether disparities in cancer treatment 
costs among Medicaid population are driven by differences in access to indicated treatment, 
coordination of care, or patient characteristics, including health status and socioeconomic 
differences.18,31,32
As stated earlier, the few prior studies that have examined the costs of breast cancer 
treatment in a Medicaid population have been conducted in state-specific or small 
geographically defined settings.9,13,14,16 As a result, the findings in these studies are not 
generalizable and may not be consistent with the national estimates reported in this paper. 
For example, Subramanian et al.9 conducted a study on treatment cost for breast cancer 
patients enrolled in Medicaid in North Carolina and estimated that the incremental costs at 
24 months after diagnosis were $22,343, $41,005, and $117,033 for those with local, 
regional, and distant breast cancers, respectively. Khanna and colleagues16 found that, for a 
woman with breast cancer in the 2005 West Virginia Medicaid population, fee-for-service 
all-cause healthcare costs were $3,321 higher (p < 0.0001).
According to the recent report to the nation on the status of cancer, rates for cancer incidence 
and mortality, including breast cancer, have continued to decline.33 Though this progress is 
important, the treatment costs are expected to continue rising into the future34 due to the 
increasing number of new cancer cases, costs of new cancer therapies, increasing use of 
chemotherapy, targeted therapies, and other anticancer drugs.35–37 Several studies have 
found that the rising cost of cancer care is a major barrier to healthcare access among cancer 
patients, particularly among racial/ethnic minorities, individuals with low SES, or those who 
are uninsured or underinsured.12,38–42 The ongoing increase in the cost of cancer treatment 
has not gone unnoticed.43–45 A recent report by IOM, “Delivering High-Quality Cancer 
Care,” included the cost of care as a component of quality of cancer care.44 Further, other 
medical organizations have identified affordability as a critical issue adversely affecting 
clinical outcomes, increased risk of recurrence, and poorer disease-free survival.46–48 In 
2013, the American Society of Clinical Oncology published “Action Brief: Value in Cancer 
Care,” which emphasized the role of oncologists in communicating with patients about the 
costs of cancer care.46
The implementation of Affordable Care Act is expected to provide many opportunities to 
increase health insurance coverage. For example, millions of Americans are newly eligible 
for Medicaid, given expansions in many states. Increasing insurance coverage can help 
reduce financial barriers to treatment and provide individuals with better access to health 
services. With increased Medicaid enrollment, Medicaid expenditures for cancer treatment 
will likely increase, including breast cancer treatment costs. In addition to implementation of 
the Affordable Care Act, it is important that public health agencies, insurance companies, 
pharmaceutical companies, and patient groups work together to identify solutions to reduce 
the rising cost of cancer care and to promote high-value, high-quality cancer care for 
millions of Americans, including low-income women newly enrolled in Medicaid.
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Limitations
This study has some limitations. First, the reported medical costs did not take into account 
the opportunity costs associated with patient time spent receiving medical care, such as 
traveling to and from care, waiting for appointments, or consulting with physicians and other 
providers. Similarly, the reported costs did not account for other nonmedical expenses, such 
as child care, lodging/respite care, food, and productivity losses for caregivers. Second, data 
used in this study lack information on the stage to measure the severity of breast cancer at 
diagnosis in the study population. Thus, the authors could not separate monthly treatment 
cost estimates by stage at diagnosis. For example, in the study, the authors could not 
ascertain whether women with ductal carcinoma in situ were included in the claims data or 
the magnitude of payment to their breast cancer treatment. As a result, they reported 
aggregate (prevalence based) monthly treatment cost estimates, which have several useful 
benefits.49 However, previous studies have reported that treatment costs increase by stage at 
diagnosis.9,50 Third, because of possible coding errors that may occur during claims process, 
the algorithm used may not have fully identified breast cancer patients. Thus, the reported 
results may underestimate the true costs of breast cancer treatment in this population. 
Fourth, data used in this study are from 2007 and the results reflect the monthly cost of 
breast cancer treatment in that year. Fifth, the analysis was focused on fee-for-service 
Medicaid; Medicaid managed care was excluded and, in recent years, the proportion of 
Medicaid recipients enrolled in Managed Care has been increasing. Sixth, because of 
potential barriers for Medicaid beneficiaries to receive adequate medical care, there is a 
tendency of undertreatment in this population. Therefore, the estimated treatment costs may 
be under-reported. Finally, the reported monthly treatment cost by point of service may not 
add up to the total cost. This is because MAX data do not provide predefined point of 
service costs. This study used MAX TOS codes to categorize outpatient, inpatient, and 
prescription drug costs. However, the variable for the total payment cost was predefined in 
the MAX database, which includes many TOS codes that cannot be easily categorized as a 
component in each of the three points of service defined for this study. This means that the 
reported cost estimates by point of service may be less than the total cost. For example, the 
sum of the estimated cost by point of service presented in Table 2 was $5,600, which is 
1.94% less than the total cost of $5,711.
Conclusions
These findings add to the growing concern about the costs of cancer care and its negative 
impact on clinical care to Medicaid populations and their families. The effects of these high 
treatment costs are more severe for younger cancer patients, who have two to five times 
higher rates of filing bankruptcy than older cancer patients.51 Therefore, there is a need for 
greater awareness beyond the oncology community about the costs imposed by breast cancer 
in younger women, especially those in Medicaid. As the Medicaid program continues to 
evolve, the treatment cost estimates reported herein could provide important input for 
decision making and planning for treatment of invasive breast cancer in the Medicaid 
population. Further, these estimates could be invaluable inputs in modeling interventions to 
estimate the cost effectiveness of invasive breast cancer treatment in women enrolled in 
Medicaid.
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Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Estimated monthly medical costs per woman with breast cancer among Medicaid enrollees 
aged 19–44 years, by race/ethnicity and by type of service.
aThe reported monthly treatment cost estimates by point of service may not add up to the 
total cost. This is because the MAX dataset does not provide predefined point of service 
costs.
bEstimate obtained through use of a one part model: GLM with gamma distribution.
cEstimate obtained through use of two-part model: logit as first stage, GLM with gamma 
distribution and log link as second stage.
**p < 0.01 and 95% CI=mean±margin of error.
GLM, generalized linear model; MAX, Medicaid Analytic eXtract.
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Table 1
Summary Statistics of Women Enrolled in Medicaid Aged 19–44 Years, by Breast Cancer History, 2007
Variable
Breast cancer 
sample (n=5,542) Comparison sample (n=4,315,514)
Matched 
comparison sample 
(n=5,542)
p-value for 
differences (breast 
cancer vs matched 
comparison)
Monthly costs by service type in 2012 U.S. $, M (SD)
 Total costs 3,492 (6,101) 850 (2,291) 1,184 (2,795) < 0.01
 Outpatient costs 1,389 (2,661) 137 (370) 169 (519) < 0.01
 Inpatient costs 721 (3,815) 195 (1,141) 306 (1,670) < 0.01
 Prescription drug costs 522 (1,276) 108 (399) 231 (555) < 0.01
Medicaid enrollment
 Proportion of the year enrolled 0.831 (0.260) 0.726 (0.308) 0.839 (0.256) 0.06
Race/ethnicity, %
 Non-Hispanic white 45.63 46.30 47.10
 Non-Hispanic black 24.69 27.20 23.45
 Hispanic/Latino 19.01 16.82 19.01
 Non-Hispanic other 10.67 9.68 10.44 0.48
Age
 19–23 years 0.82 31.44 0.83
 24–28 years 3.43 25.10 3.28
 29–33 years 8.90 17.16 8.75
 34–38 years 22.58 13.47 22.78
 39–44 years 64.26 12.83 64.35 0.99
Charlson Index score
 0 82.78 92.74 81.30
 1 12.44 5.59 13.13
 >1 4.78 1.67 5.58 0.15
Comorbidities
 Cancer diagnosis 3.86 0.35 3.74 0.77
 Hypertension 11.36 3.61 12.01 0.36
 Dyslipidemia 4.65 1.32 5.11 0.34
 Pneumonia 3.54 0.70 3.56 0.97
 Asthma 5.27 2.87 5.83 0.27
 Depression 9.74 5.78 9.86 0.86
 Back problems 10.91 5.10 11.70 0.26
 Skin disorders 8.80 3.01 8.91 0.87
 Injuries 16.83 5.40 17.22 0.64
 Pregnancy 3.82 30.63 3.86 0.94
 Arthritis 8.11 2.82 8.86 0.23
 Mental health/substance abuse 17.00 10.49 17.68 0.42
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Variable
Breast cancer 
sample (n=5,542) Comparison sample (n=4,315,514)
Matched 
comparison sample 
(n=5,542)
p-value for 
differences (breast 
cancer vs matched 
comparison)
 Mental retardation 1.14 1.77 1.00 0.56
Note: State dummies were included in the match. Boldface indicates statistical significance. The p=0.01 level indicates statistically significant 
differences between the breast cancer sample and the matched comparison sample was 0.987. The Charlson Index is exclusive of cancers. The 
values for this index range from 0 to 15. Cancer diagnosis includes one of the following cancers: ovarian cancer, colorectal cancer, lung cancer, 
cervical cancer, skin cancer, leukemia and lymphoma.
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Table 2
Estimated Monthly Breast-Cancer Attributable Medical Care Costs per Woman With Breast Cancer Among 
Medicaid Enrollees Aged 19–44 years, by Point of Service
Point of servicea Overall (n = 11,084) 95% CI, U.S.$
Total costsb $5,711 5,039, 6,383
Outpatientb $4,058 3,575, 4,541
Inpatientc $1,003 708, 1,298
Prescription drug costsc $539 430, 647
Note: Boldface indicates statistical significance (p < 0.01).
a
The reported monthly treatment cost estimates by point of service may not add up to the total cost. This is because MAX dataset does not provide 
predefined point of service costs. In the study, we used the MAX Type of service codes to categorize the outpatient, inpatient, and prescription drug 
costs. However, the variable for the total payment cost was predefined in MAX database, which includes many type of service codes that cannot be 
easily categorized as a component in each of the three points of service defined for this study. This means that the reported cost estimates by point 
of service will be less than the total cost. For example, the sum of the estimated cost by point of service presented in this Table was $5,600, which 
is 1.94% less than the total of $5,711.
b
Estimate obtained through use of a one part model: generalized linear model with gamma distribution.
c
Estimate obtained through use of two-part model: logit as first stage, generalized linear model with gamma distribution and log link as second 
stage. Further, the inpatient and prescription drug costs regressions have zeroes in >10% of the sample, which necessitated the use of a two-part 
model.
MAX, Medicaid Analytic eXtract.
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